Eloctate
Payments companies reported to CMS as associated with Eloctate. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Eloctate, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Eloctate
These are the largest totals companies reported as associated with Eloctate. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Lynn Malec | Milwaukee, WI | Pediatric Hematology-Oncology | $26,677.61 |
| Angela Weyand | Ann Arbor, MI | Pediatric Hematology-Oncology | $20,445.84 |
| Doris Quon | Los Angeles, CA | Hematology (Internal Medicine) | $20,126.85 |
| Robert Sidonio | Atlanta, GA | Pediatric Hematology-Oncology | $9,714.58 |
| Michael Guerrera | Washington, DC | Pediatric Hematology-Oncology | $8,756.82 |
| Vanessa Salinas-Luna | Orange, CA | Pediatric Hematology-Oncology | $3,532.67 |
| Ariel Levy | Washington, DC | Pediatrics (Nurse Practitioner) | $3,275.64 |
| Jonathan Roberts | Peoria, IL | Pediatrics | $3,164.00 |
| Joanna Davis | Miami, FL | Pediatric Hematology-Oncology | $2,718.00 |
| Margaret Ragni | Pittsburgh, PA | $1,250.00 |
Prescribed Eloctate?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.